Coya Therapeutics reports Q2 EPS (36c), consensus (43c)

Reports Q2 revenue $200K, consensus $668.57K. As of June 30, 2025, Coya had cash and cash equivalents of $29.8M. CEO Arun Swaminathan commented, “As we look ahead, we are focused on several key catalysts, including a decision from the FDA on our IND application for COYA 302 in ALS, anticipated by the end of August. We are encouraged by the growing body of data supporting our regulatory T cell enhancement approach, including the recent findings from the investigator-initiated trial in FTD and promising pre-clinical results with COYA 303. These advances strengthen our confidence in the potential of COYA 302 in neurodegenerative diseases like ALS and FTD.” Chief Medical Officer Fred Grossman commented, “We look forward to the FDA’s decision on our IND submission for COYA 302 in ALS, which represents a significant milestone for our lead program. Pending clearance, we are prepared to initiate our controlled Phase 2 clinical trial in ALS. We also plan to submit an IND for FTD by the end of the year.”